Drug General Information (ID: DDICNBFREP)
Drug Name			Natalizumab		Drug Info		Glatiramer		Drug Info
Drug Type		Monoclonal antibody				Protein/peptide
Therapeutic Class		Selective Immunosuppressants				Immunomodulatory Agents

Mechanism of Natalizumab-Glatiramer Interaction (Severity Level: Major)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Natalizumab				Glatiramer
Mechanism		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Natalizumab and Glatiramer

Recommended Action
Management		The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been evaluated. Patients receiving such agents should not be treated with natalizumab because of the possibility of increased risk of infections, including PML. However, short courses of corticosteroids may be given. All patients treated with natalizumab should be monitored closely and the drug discontinued immediately at the first sign or symptom suggestive of PML, although it is not known if early detection of PML and discontinuation of natalizumab will mitigate the disease.

References
1	Product Information. Tysabri (natalizumab). Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.